It is becoming increasing evident that radiotherapy (RT) may benefit from coincident or subsequent immunotherapy. In this study, we examined whether the anti-tumor effects of RT, in established triple-negative breast tumors could be enhanced with combinations of clinically relevant monoclonal antibodies (mAbs), designed to stimulate immunity (anti (α)-CD137, α-CD40) or relieve immunosuppression (α- 
Introduction
Along with surgery and chemotherapy, RT is one of the most important anti-cancer therapies. Indeed, nearly two-thirds of all cancer patients will receive RT during their course of treatment. RT has long been employed for its powerful anti-proliferative and death-inducing capacities. Recent preclinical and clinical data, however, indicate that immunogenic cell-death may also be an important consequence of ionizing radiation (1) and that localized RT can evoke and/or modulate tumor-associated immune responses (2) (3) . Collectively, these findings have set the stage for examining the therapeutic impact of combined RT and immunotherapy.
Pre-clinical studies evaluating the combined therapeutic effects of RT and immunotherapy have employed the use of virus and dendritic cell (DC)-based vaccines (4-5), toll-like receptor (TLR) agonists, such as CpG oligodeoxynucleotides (6) and recombinant cytokines (7) . In addition, RT has been trialed in conjunction with monoclonal antibodies (mAbs) that target co-stimulatory molecules such as CD40, CD137, OX40 (CD134) or the checkpoint inhibitor CTLA-4 (8) (9) (10) (11) (12) . While these studies have demonstrated that single immunomodulatory agents can enhance the anti-tumor effects of RT, tumor cures were rare, particularly against poorly immunogenic tumors.
Tumor-induced immune-tolerance and immunosuppression (13) (14) may restrict the success of radio-immunotherapeutic approaches. In order to overcome such immunological barriers to effectively control established disease, a rational combination of multiple immunomodulatory agents and standard anti-cancer regimens
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Author Manuscript Published OnlineFirst on May 8, 2012 ; DOI: 10.1158/0008-5472. is likely required. Indeed, we and others have demonstrated that combining mAbs targeting CD40, CD1d and/or CD137, designed to modulate DC and T-cell activity respectively are highly effective, particularly in combination with TRAIL-receptor agonists and histone deacetylase inhibitors (HDACi) in eradicating established solid tumors (15) (16) (17) . However, given the intrinsic resistance of many tumors to TRAILreceptor agonists and HDACi, as well as the fact that TRAIL-receptor agonists are still in clinical development and the applicability of HDACi is currently largely restricted to hematological malignancies, the broader application of these combinations is presently limited (18) (19) . Blockade of immune checkpoint-inhibitory molecules such as CTLA-4 or PD-1, alone or in combination with anti (α)-CD137 therapy also increased the therapeutic activity of vaccine approaches and α-erbB2 therapy (20) (21) . To date however, the therapeutic benefit of targeting multiple immune stimulatory and/or inhibitory pathways in combination with RT has not been described.
Here, we demonstrate that mAbs to CD137, CD40 and PD-1, which are all in clinical development, combined with single-and low-dose fractionated RT, induced the rejection of established subcutaneous and orthotopically implanted, triple-negative and checkpoint-inhibitory mAbs as adjuvants to RT in breast cancer treatment.
Author Manuscript Published OnlineFirst on May 8, 2012 ; DOI: 10.1158/0008-5472.CAN-12-0210 7 staining, and (ii) apoptosis by caspase-3 cleavage as described (25). Clonogenic assays were essentially performed as described (26). Briefly, cells were plated at increasing densities of up to 8,000 cells/10cm dish. After adhering (4-6h at 37°C), cells were irradiated (0-10Gy). After 8-11 days of incubation under normal culture conditions, cells were stained with 2.5% glutaraldehyde and 0.05% crystal violet for >15min at room temperature. Colonies (>40 cells) were counted using an inverted microscope and clonogenicity of untreated cells (0Gy) was set to 100%.
TUNEL staining
Mice bearing 20- 
Phenotyping of tumor cells and tumor-infiltrating lymphocytes
Expression of PD-L1 on in vitro cultured and explanted tumor cells, prior to and 12-96h post radiation treatment (0-30Gy in vitro; 12Gy in vivo) was assessed by flow cytometry as described (27) using biotinylated α-mouse CD274 (PD-L1, BD Pharmingen) mAb and allophycocyanin (APC)-conjugated streptavidin (eBioscience).
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Therapeutic Antibodies and Reagents
The rat mAb to mouse CD137 (3H3, IgG2a) was generated in house as described (28) and protein-G purified or purchased from BioXCell (New Hampshire, USA). The rat α-mouse CD40 mAb (FGK4.5, IgG2a) was from WEHI. The rat α-mouse PD-1 mAb (RMP1-14; 1gG2a) was prepared as described (29). Depleting antibodies to asialoGM1 (NK-cells; Wako Pure Chemical, Osaka, Japan), mouse CD4 (GK1.5) and CD8β (53-5.8; BioXCell) were prepared as described (30). For both therapy and depletion studies, MAC4 mAb was used as the isotype control (28).
Therapy of transplanted tumors
Mice were anesthetized with ketamine (100mg/kg) and xylazine (10mg/kg) or isofluorane and injected with 4T1. 
Results
Ionizing radiation induces cell death in triple-negative mammary tumor cells.
In vitro assay systems were initially employed to screen the BALB/c-derived 4T1.2 and C57BL/6-derived AT-3 triple-negative mammary tumor lines for their sensitivity to ionizing radiation. Radiation-induced cell death as determined by Annexin-V/PI staining was evident in both cell-lines and occurred in a time-and dose-dependent manner (Fig.1A,B (top panels) ). In 4T1.2 cells, radiation-induced cell death was not affected by the pan-caspase inhibitor qVD (Fig.1A) or over-expression of the antiapoptotic protein Bcl-2 (data not shown). In addition, caspase-3 cleavage was not detected in irradiated 4T1.2 cultures (data not shown); collectively indicating that apoptosis was not the primary mechanism of radiation-induced 4T1.2 cell death. In contrast, caspase-3 cleavage was detected in irradiated AT-3 cultures (Fig.1B) . Overexpression of Bcl-2 (data not shown) or treatment with qVD (Fig.1B, top panels) significantly reduced Annexin-V/PI staining, indicating that apoptosis contributed to radiation-induced AT-3 cell death. Despite these mechanistic differences the radiosensitivity of 4T1.2 and AT-3 tumor cells, as determined in long-term clonogenic assays, was comparable (Fig.1C) . Although a percentage (40%) of tumor-bearing mice were found to be highly responsive to RT and α-CD40 treatment ( Fig.2A) , α-CD40 therapy did not further enhance the therapeutic response of AT-3 tumors to RT/α-CD137 treatment ( Fig.2A) .
Interestingly, however, in established subcutaneous 4T1.2 tumors RT/α-CD40/α-CD137 therapy was found to be curative in >80% of mice (Suppl. We next determined whether α-CD137/α-PD-1 therapy promoted the rejection of irradiated AT-3 tumors in the physiologically relevant tissue microenvironment of the mammary fatpad. Notably, orthotopic AT-3 tumors expressed PD-L1 at levels similar to subcutaneous tumors (data not shown). Combined effects were observed with RT and α-CD137, α-PD-1 and α-CD137/α-PD-1 therapy (Fig.4A,B) . Strikingly, up to a 100% rejection-rate was achieved when RT was combined with both α-CD137 and α-PD-1 mAbs. Consistent with our observations in subcutaneous AT-3 tumors, α-CD137 therapy showed single-agent activity, while α-PD-1 treatment did not.
However, α-PD-1 treatment prolonged the therapeutic response of orthotopic AT-3 tumors to α-CD137 therapy and significantly enhanced the anti-tumor effect of RT in a small percentage of mice (Fig.4A,B) . These results reaffirm the importance of PD-1 as a possible immunotherapeutic target in breast cancer. of RT/α-CD137/α-PD-1 therapy in subcutaneous AT-3 tumors (Fig.3D) .
Characterization of a persistent
Interestingly, CD137 expression was only detected on a subset of PD-1 High -expressing
CD8
+ T-cells (Fig.5A ). The majority of CD8 + T-cells in AT-3 tumors expressed low levels of PD-1 and were negative for CD137 (Fig.5A) . Notably, CD137 and PD-1 expression was also observed on tumor-associated NK and CD4 + T-cells (data not shown 
between 12 and 36h post RT (Fig.5B) . Despite these differences, both the PD-1 High and PD-1
Low

CD8
+ T-cell subsets possessed similar levels of Granzyme B, which was increased at 36h post RT (Fig.5E ). Further to this, the PD-1 High and PD-1 Low CD8 + Tcell subsets were equally capable of producing IFN-γ in response to PMA and ionomycin (Fig.5F ), suggesting that both were functionally active ex vivo.
Importantly, these functionally responsive populations of CD137 Similar to what was observed in the parental AT-3 tumors, CD137 expression was restricted to the PD-1 High CD8 + T-cell subset (Fig.6A) , which was enriched for at 12h
following RT (Fig.6A,B) . Importantly, only cells within the PD-1 High CD137 + CD8 + Tcell population were OVA-tetramer reactive and thus tumor antigen-specific (Fig.6C) , which indicates that RT enriches the tumor microenvironment for tumor-specific CD8 + T-cells.
Fractionated RT in combination with immunotherapy induces regression of orthotopic mammary tumors.
Although our data so far highlight the therapeutic potential of radio-immunotherapy for the treatment of breast cancer, in the clinic, patients typically receive a series of
Research. achieving rejection rates of 40% and 60%, respectively (Fig.7A,B) . The finding that antibody-based immunotherapy enhanced the anti-tumor response to low-dose fractionated RT demonstrates the clinical potential of this radio-immunotherapeutic approach for treating established breast cancer.
Discussion
To our knowledge, this is the first preclinical study to examine the therapeutic impact of combining multiple stimulatory and/or inhibitory mAbs with RT and the cellular mechanisms underlying these responses in established breast cancer. We demonstrate in two distinct models of triple-negative mammary cancer that unique combinations of radio-immunotherapy are capable of curing mice of established disease. Radio- Given the efficacy of α-CD137 therapy in irradiated AT-3 and 4T1.2 tumors, we predicted that antibody-based targeting of other co-stimulatory receptors might mediate similar therapeutic effects. The CD137-family member OX40 has been reported to enhance CD8 + T-cell-dependent anti-tumor effects of RT in highly immunogenic OVA-expressing Lewis lung carcinoma and MCA205 sarcoma (8, 43) and was therefore of particular interest. Surprisingly however, α-OX40 therapy did not enhance the therapeutic efficacy of RT in 4T1.2 (Suppl. Fig.6A ) and AT-3 tumors (Suppl. Fig.6B ). The reasons for the lack of α-OX40 activity in these models remain unresolved; however α-CD137 therapy can also directly alter expression of adhesion 
